APA (7th ed.) Citation

M, F., A, G., J, W., F, K., S, R., F, F., . . . P, C. (2024). Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial. Blood, 144(3), 272. https://doi.org/10.1182/blood.2023022730

Chicago Style (17th ed.) Citation

M, Fürstenau, et al. "Acalabrutinib, Venetoclax, and Obinutuzumab in Relapsed/refractory CLL: Final Efficacy and CtDNA Analysis of the CLL2-BAAG Trial." Blood 144, no. 3 (2024): 272. https://doi.org/10.1182/blood.2023022730.

MLA (9th ed.) Citation

M, Fürstenau, et al. "Acalabrutinib, Venetoclax, and Obinutuzumab in Relapsed/refractory CLL: Final Efficacy and CtDNA Analysis of the CLL2-BAAG Trial." Blood, vol. 144, no. 3, 2024, p. 272, https://doi.org/10.1182/blood.2023022730.